These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15720272)

  • 21. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering causes and cures for cancer from gene expression analysis.
    Weeraratna AT
    Ageing Res Rev; 2005 Nov; 4(4):548-63. PubMed ID: 16243590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits.
    Kerb R; Brinkmann U
    Pharmacogenomics; 2001 Aug; 2(3):303-5. PubMed ID: 11939136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity.
    Auman JT; McLeod HL
    Drug Metab Rev; 2008; 40(2):303-15. PubMed ID: 18464047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
    O'Donnell PH; Ratain MJ
    Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of molecular profiling in clinical trials for advanced metastatic cancers.
    Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
    Burczynski ME; Twine NC; Dukart G; Marshall B; Hidalgo M; Stadler WM; Logan T; Dutcher J; Hudes G; Trepicchio WL; Strahs A; Immermann F; Slonim DK; Dorner AJ
    Clin Cancer Res; 2005 Feb; 11(3):1181-9. PubMed ID: 15709187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent advances in pharmacogenomics in oncology].
    Robert J; Bonnet J
    Bull Cancer; 2004 Jan; 91(1):19-28. PubMed ID: 14975802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug development in oncology: classical cytotoxics and molecularly targeted agents.
    Kummar S; Gutierrez M; Doroshow JH; Murgo AJ
    Br J Clin Pharmacol; 2006 Jul; 62(1):15-26. PubMed ID: 16842375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
    Calvo E; Walko C; Dees EC; Valenzuela B
    Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics in early-phase clinical development.
    Burt T; Dhillon S
    Pharmacogenomics; 2013 Jul; 14(9):1085-97. PubMed ID: 23837482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalised medicine for cancer: from drug development into clinical practice.
    Jain KK
    Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
    Nishiyama M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1902-7. PubMed ID: 16282724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Gene Profiling for Response Prediction.
    Ghadimi BM; Jo P
    Methods Mol Biol; 2016; 1381():163-79. PubMed ID: 26667460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why most gene expression signatures of tumors have not been useful in the clinic.
    Koscielny S
    Sci Transl Med; 2010 Jan; 2(14):14ps2. PubMed ID: 20371465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.